By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...